RST-01 Origins
RST-01 (Fluoro Ethyl Nor-Memantine) has its origin from its 18F analogue, assessed in collaboration with the Hospital-University of Toulouse, France, as the first highly selective and functional NMDA receptor radiotracer.
Rationale
From the high selectivity of RST-01 to NMDA receptor, came the conclusion that non-radioactive RST-01could be an ideal candidate to treat CNS diseases in which balanced activation and blockade of NMDA receptor activity is involded. Building a strong network of academic partners (University of Columbia – New York, University of Montpellier, CNRS Toulouse, Ecole Normale Superieure Paris), ReST has been able to acquire evidence that the differentiated effects of FENMRST-01 on NMDA subtypes should enable a full recovery from traumatic stress, paving the way for a development as a secondary prophylactic for PTSD.
Disabled by AD (Worldwide)
Suffering from long lasting PTSD (USA & EU)
Publications
Published patents
FENM – Scientific Documentation
Patents
-
2013 – EP3003399 – novel chemical compounds derived from normemantine and use of same in the medical field
-
2017 – EP3723742 – use of fluoroethylnormemantine for the prevention and treatment of anxiety
-
2020 – WO2021234324 – compound and composition for inducing neuroprotection
-
2021 – WO2023079187 – new synergistic combinations based on fenm and an acetylcholinesterase inhibitor
- 2020 – EP3968977 – compositions and methods against stress-induced affective disorders and their associated symptoms
Publications
FENM as a Biomarker
-
Anne-Sophie Salabert et al.; Radiolabeling of [18F]-fluoroethylnormemantine and initial in vivo evaluation of this innovative PET tracer for imaging the PCP sites of NMDA receptors; Nuclear Medicine and Biology (2015)
-
Anne-Sophie Salabert et al.; Evaluation of [18F]FNM biodistribution and dosimetry based on whole-body PET imaging of rats; Nuclear Medicine and Biology (2018)
-
Marie Beaurain et al.; Pharmacological Characterization of [18F]-FNM and Evaluation of NMDA Receptors Activation in a Rat Brain Injury Model; Mol Imaging Biol. (2023)
FENM as a Drug candidate
- Simon Couly et al.; Anti-amnesic and neuroprotective effects of Fluoroethylnormemantine in a pharmacological mouse model of Alzheimer’s disease; International Journal of Neuropsychopharmacology (2020)
- Fluoroethylnormemantine, A novel derivative of memantine, facilitates extinction learning without sensorimotor deficits Briana K. Chen et al., International Journal of Neuropsychopharmacology (2021)
- Fluoroethylnormemantine, a Novel NMDA Receptor Antagonist, for the Prevention and Treatment of Stress-Induced Maladaptive Behavior. Briana K.Chen et al., Biological Psychiatry (2021)
- Freyssin A, Carles A, Guehairia S, Rubinstenn G, Maurice T. Fluoroethylnormemantine (FENM) shows synergistic protection in combination with a sigma-1 receptor agonist in a mouse model of Alzheimer’s disease. Neuropharmacology (2023)